The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?

Sharma, Abhipree; Mah, Michael K S; Ritchie, Rebecca H.; De Blasio, Miles J.

doi:10.1016/j.pharmthera.2021.108008

Record: found
Abstract: not found
Article: not found

The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?

Author(s): Abhipree Sharma , Michael Mah , Rebecca H. Ritchie , Miles J. De Blasio

Publication date Created: April 2022

Publication date (Print): April 2022

Journal: Pharmacology & Therapeutics

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 306

Record: found
Abstract: found
Article: not found

WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition

Pouya Saeedi, Inga Petersohn, Paraskevi Salpea … (2019)

To provide global estimates of diabetes prevalence for 2019 and projections for 2030 and 2045.

0 comments Cited 2799 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

0 comments Cited 2503 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E Inzucchi … (2020)

In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.